18/12/2025 15:57
Morgan Stanley lowered the target price for CSPC Pharma (01093) to HKD10.4 from HKD11 and maintained the "overweight" rating.
The research house said it now projects sales and recurring net profit growth of +5% and +7% in 2026, accelerating to +6% and +10% in 2027, respectively, as new product launches gain traction.
【說說心理話】如何從小孩子的行為察覺他們心理上有壓力？播道兒童之家院長個案分享► 即睇
下一篇新聞︰16/12/2025 16:08 {I-bank focus}Citi raises China Shenhua (01088) to HKD45.1
16/12/2025 14:43 {I-bank focus}Morgan lowers ZTE (00763) to HKD31.5
15/12/2025 16:00 {I-bank focus}Citi raises Li Ning (02331) to HKD20.6
15/12/2025 14:35 {I-bank focus}Morgan raises Ali Health (00241) to HKD4.6
12/12/2025 16:08 {I-bank focus}Citi lowers China Res Power (00836) to HKD19
12/12/2025 14:40 {I-bank focus}Morgan raises COSCO Ship Hold to HKD10.3
